Dubravka Vuković

Dr. Dubravka Vuković

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
AČAntoanela Čarija
Antoanela Čarija
NPNeira Puizina-Ivić
Neira Puizina-Ivić
DVDubravka Vuković
Dubravka Vuković
LKLina Mirić Kovačević
Lina Mirić Kovačević
VČVesna Čapkun
Vesna Čapkun

7 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BPBerna Pavic
Berna Pavic
MOMarin Ogorevc
Marin Ogorevc
KBKatarina Boric
Katarina Boric
DVDubravka Vuković
Dubravka Vuković
MSMirna Saraga-Babić
Mirna Saraga-Babić
SMSnjezana Mardesic
Snjezana Mardesic
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although its pathogenesis is not fully understood, connexins (Cxs) and pannexins (Panx) could be involved in the process of fibrosis. We analyzed the protein expression of Cx37, Cx40, Cx43, and Panx1 in the gastric mucosa of patients with SSc and healthy volunteers, using immunofluorescence staining. Protein levels of Cx37 were slightly increased, while the levels of Cx40 were significantly decreased in the lamina propria of the gastric mucosa of SSc patients compared to the controls. The changes were proportional to SSc severity, with the most prominent changes found in patients with severe diffuse cutaneous SSc. No differences in Cx43 or Panx1 levels were found between the analyzed groups of samples. The lack of changes in Cx43 expression, which has been previously associated with fibrosis, could be due to the weak expression of Cx43 in the gastric mucosa in general. Further studies on full-thickness gastric biopsies containing muscle layers and animal SSc models are needed to fully elucidate the role of Cxs and Panxs in SSc-associated fibrosis.

18 December 2024 in Life
Verified
Journal Article
Open access
PDF file
Doris RusicDoris Rusic
Doris Rusic
MIMagdalena Ivic
Magdalena Ivic
ASAna Slugan
Ana Slugan
Dario LeskurDario Leskur
Dario Leskur
Darko ModunDarko Modun
Darko Modun
Ana Seselja PerisinAna Seselja Perisin
Ana Seselja Perisin
The literature describes niacinamide, but also postbiotics and peptides, as ingredients that improve skin barrier function, but also affect melanin and sebum levels in individuals. However, the combined effects of these ingredients in a single cosmetic serum have not been sufficiently investigated. Therefore, the aim of this randomized controlled study, conducted at the University of Split School of Medicine (Croatia), was to evaluate the effects of cosmetic products containing these active ingredients. This study was registered with ClinicalTrials.gov (NCT06189105) and has been completed. Primary outcomes were the levels of trans epidermal water loss, skin hydration, erythema, melanin, and sebum, all measured in 25 healthy Caucasian participants. Significant differences between hydration levels were observed at week 4 (61.0 ± 11.2 vs. 68.6 ± 13.3 AU, control and intervention). Moreover, a significant decrease in erythema values from the first to last measurement in the intervention group was observed, (379.9 ± 106.8 vs. 333.6 ± 73.5 AU, baseline values and week 4, intervention group). Interestingly, both the increase in skin hydration levels and the decrease in skin erythema after niacinamide serum application were significant in study participants who did not use sun protection products. It is well known that ultraviolet radiation has detrimental effects on human skin, and our results suggest that niacinamide could help counteract these effects.

11 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ITIvo Tripković
Ivo Tripković
MOMarin Ogorevc
Marin Ogorevc
DVDubravka Vuković
Dubravka Vuković
MSMirna Saraga-Babić
Mirna Saraga-Babić
SMSnježana Mardešić
Snježana Mardešić
Carpal tunnel syndrome (CTS) and Dupuytren’s disease (DD) are fibrotic conditions that affect the connective tissue of the hand and limit its functionality. The exact molecular mechanism underlying the fibrosis is unknown, and only some profibrotic factors have been investigated. In this cross-sectional study, we analyzed the expression of FGF signaling pathway molecules associated with fibrotic changes in the palmar fascia and the flexor retinaculum of 15 CTS patients and both clinically affected and unaffected palmar fascia of 15 DD patients, using immunofluorescence techniques. The expression of FGFR1, FGFR2, and CTGF in the blood vessel walls and surrounding connective tissue cells differed significantly between the analyzed groups, with changes in expression present even in clinically unremarkable tissues from DD patients. We also found altered expression of the analyzed factors, as well as TGF-β1 and syndecan-1 in DD-associated sweat glands, possibly implicating their role in the pathophysiology of the disease. The increased expression of profibrotic factors in the clinically unaffected palmar fascia of DD patients may indicate that more extensive excision is needed during surgical treatment, while the profibrotic factors could be potential targets for developing pharmacological therapeutic strategies against DD-associated fibrosis.

19 April 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
SPShelly Melissa Pranić
Shelly Melissa Pranić
APAnika Pulumati
Anika Pulumati
DVDubravka Vuković
Dubravka Vuković
Background: Vitiligo is a disease that affects people of all skin shades and can impact their quality of life. Reliable evidence on the effectiveness and adverse events associated with the recent use of Janus kinase (JAK) inhibitors to treat vitiligo is needed. This protocol for a systematic review and meta-analysis seeks to collect evidence from both randomized controlled trials (RCTs) and observational studies to determine the effectiveness and patient-centered outcomes concerning treatment with JAK inhibitors. Methods: We will conduct a systematic review of the literature for RCTs and observational studies that used upadacitinib, ritlecitinib, brepocitinib, ifidancitinib, cerdulatinib, deglocitinib, baricitinib, tofacitinib, and ruxolitinib JAK inhibitors as treatments for vitiligo compared to placebo, no treatment, or combination therapies. We will systematically search from inception in Epistemonikos, MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, EMBASE, ClinicalTrials.gov, PsycINFO, Allied and Complementary Medicine Database, Latin American and Caribbean Health Sciences Literature, Web of Science Core Collection, relevant preprint servers, and the gray literature. Ethics approval was not sought as the protocol and systematic review will not involve human participants, but rather summarized and anonymous data from studies. Primary outcomes include quality of life, percentage repigmentation, decreased vitiligo within 1 year or more, lasting repigmentation after a 2-year follow-up, cosmetic acceptability of repigmentation and tolerability or burden of treatment, and adverse events. Secondary outcomes are patient and study characteristics. We will include full-text articles, preprints, and clinical trial data in any language and all geographic regions. For data sources unavailable in English, we will obtain translations from global collaborators via the Cochrane Engage network. We will exclude articles for which sufficient information cannot be obtained from the authors of articles and systematic reviews. At least two investigators will independently assess articles for inclusion and extract data; reliability will be assessed before subsequent selection and data extraction of remaining studies. The risk of bias and certainty of evidence with Grading of Recommendations Assessment, Development, and Evaluation guidelines will be assessed independently by at least two investigators. We will estimate treatment effects by random-effects meta-analyses and assess heterogeneity using I2. Data that cannot be included in the meta-analysis will be reported narratively using themes. Discussion: The proposed systematic review and meta-analysis describe the methods for summarizing and synthesizing the evidence on the effectiveness and patient-centered outcomes concerning the treatment of vitiligo with JAK inhibitors that were recently approved for this indication. To disseminate further the results of our systematic review, we plan to present them at international conferences and meetings. Our findings will provide robust evidence to facilitate decision-making at the policy or practitioner level. Systematic review registration: PROSPERO CRD42023383920.

27 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
DVDubravka Vuković
Dubravka Vuković
MOMarin Ogorevc
Marin Ogorevc
ITIvo Tripković
Ivo Tripković
NPNeira Puizina-Ivić
Neira Puizina-Ivić
MSMirna Saraga-Babić
Mirna Saraga-Babić
SMSnježana Mardešić
Snježana Mardešić
Lichen sclerosus (LS) is a progressive skin disease that is characterized by chronic inflammation of either genital or extragenital skin, and it disproportionately affects women. We analyzed the distribution of nerve fibers, vanilloid receptors, cell proliferation, mast cells and macrophages in genital and extragenital LS samples, as well as in healthy skin, by using immunohistochemistry. The total amount of intraepidermal nerve fibers was lower in LS samples compared to healthy controls, while the total amount of subepidermal nerve fibers and calcitonin gene-related peptide (CGRP) positive fibers was higher in genital LS samples compared to both extragenital LS and healthy controls. Cell proliferation, macrophage and mast cell density were increased in LS samples compared to healthy controls. Genital LS had a higher macrophage density compared to the extragenital variant. Mast cell distribution significantly differed between genital and extragenital LS samples, even though their total mast cell densities were similar. These findings could explain the differences between pruritic symptoms of genital and extragenital LS and provide targets for the research of novel therapeutic strategies for LS management.